L3 Fungal Infections in the Immunocompromised Flashcards

1
Q

3 Different Fungal Forms? Examples of each?

A
  1. Molds (filamentous) e.g. Aspergillus, Mucor
  2. Yeasts e.g. Candida, Cryptococcus
  3. Dimorphic fungi – can exist in mold and yeast forms e.g. Histoplasma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Lab Diagnosis of Fungal Infections?

A

Microscopy
* Gram stain
* Fungal stains

Culture
* Blood agar
* Sabouraud dextrose agar (SDA)

Antigen detection
* BD-glucan (non-specific, part of cell wall of most fungi but NOT Mucorales) - serum
* Galactomannan (suggestive of Aspergillus) – serum, BAL (useful as usually respiratory)
* Cryptococcal antigen (CrAg (suggestive of Cryptococcus)– serum, CSF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Why do fungal infections occur in IC patients?

A

Inability to respond normally to infection

  • T-cell defects
  • B-cell defects (Inadequate antibody production)
  • Neutrophil defect or deficiency (Responsible for first line innate defense)
  • Mucosal defects (GI Mucosa key for preventing ingested pathogens being absorbed)
    Chemo patients prone to mucosal damage - Esp get Candida
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Fungal Infections in the immunocompromised?

A

Candida

Aspergillus: ubiquitous, construction tends to release spores into air

Mucormycetes – Mucor, Rhizopus

Cryptococcus Neoformans

Endemic mycoses - Histoplasma etc.

Pneumocystis Jiroveci

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Prevention of fungal infections in the immunocompromised?

A

Environmental protection
* Cleaning
* Provision of HEPA filtered air

Antifungal prophylaxis
* High risk IC groups (Stem cell, post liver transplant)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Prevention of fungal infections in the immunocompromised?

A

Environmental protection
* Cleaning
* Provision of HEPA-filtered air

Antifungal prophylaxis
* High risk IC groups (Stem cell, post liver transplant)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Localized Manifestations of Canida Infection: Predispositions/Treatment?

A

Oropharyngeal
Predisposed by:
* Cellular immunodeficiency e.g., HIV, CD4 <200
* Antimicrobial treatment
* Chemotherapy
* Radiotherapy to head and neck

Treatment
Topical: clotrimazole, miconazole
Oral: azole

Esophagitis
_Manifests as:_Odynophagia (pain on swallowing), retrosternal

Predisposed by:
* Cellular immunodeficiency e.g., HIV, CD4 <200
* Hematological malignancy
* Inhaled corticosteroids ((Bronchiectasis, COPD)

Treatment: Systemic fluconazole (po or iv) – 14-21 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Invasive Candida infection in Immunocompromised: Manifestation/Treatment

A

Candida bloodstream infection most common
* Hematological malignancy
* Total parenteral nutrition
* Transplant (SOT and BMT)
* Chemotherapy
* Severely ill in ICU

Treatment of Bloodstream Candida Infections
* Echinocandin initially, modify according to susceptibilities
* Minimum 2 week IV therapy

  • Remove line
  • Ophthalmology review (rule out endophthalmitis)
  • Echocardiogram (rule out fungal endocarditis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Chronic Disseminated Candidiasis: Risk Factors/Manifestation/Diagnosis/Management

A

Risk Factors:
Hematological malignancy (Neutropenic for weeks => prone to invasive infection)
Recent neutropenia

Manifestation
* Persistent high fevers
* Right Upper Quadrant pain/discomfort
* Nausea, anorexia, vomiting
* Elevated alkaline phosphatase

Diagnosis
*LESSIONS THROUGHOUT LIVER
* Imaging – CT, MRI
* Biopsy to confirm– granulomata, yeasts

Management
Echinocandin or Amphotericin B

Minimum 6 months, until resolution of lesions on imaging

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Management of various forms of Candida Infection

A

Treatment of Oropharyngeal Candida infection
Topical: clotrimazole, miconazole
Oral: azole

Treatment of Esophagitis
Systemic fluconazole (po or iv) – 14-21 days

Treatment of Bloodstream Candida Infections
Echinocandin initially, modify according to susceptibilities
Minimum 2 week IV therapy

Treatment of Disseminated Candidiasis
Echinocandin or Amphotericin B
–Oral azole as step-down
Minimum 6 months, until resolution of lesions on imaging

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Risk Factors for Invasive Aspergillosis infection?

A

Prolonged neutropenia (> 14 days) e.g., AML
Diabetes mellitus
High dose steroids

Transplant (BMT/ SOT)
HIV (rare < 1%
COVID, influenza

Outbreaks associated with hospital construction/refurbishment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Pathogenesis/Clinical Features of Invasive Aspergillosis?

A

Pathogenesis
Primary site is lung (Spores inhaled)=> Widespread destructive growth in lung tissue => Invasion of blood vessels (angioinvasive)=> Dissemination to other sites (liver, spleen, kidney, CNS)

Poor prognosis (80% mortality) !!

Clinical Features
Non-specific
Fever – refractory to antibacterials
Cough, Dyspnea, Chest pain
RARE: Skin lesions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Imaging/Diagnosis of Invasive Aspergillosis?

A

Imaging
CXR – not useful!

High-resolution CT thorax
* Nodules/Cavitation => think fungal
* Consolidation
* Peri-bronchial infiltrates

Highly suggestive of fungal infection:
Halo sign: lucency around the nodule
Air-crescent sign

Diagnosis
Gold Standard is histology (Lung Biopsy) – septate hyphae

Respiratory culture (BAL > sputum): Presence in sputum not indicative of invasive aspergillosis
Galactomannan (antigen) in blood and BAL
Antibodies – WASTE OF TIME, only shows past exposure to infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are septate hyphae on tissue biopsy histology diagnostic of?

A

Invasive Aspergillosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are Halo sign and Air-crescent signs on a CT Thorax scan suggestive of?

A

Invasive Aspergillosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Outbreaks associated with demolition and construction work – heavy contamination of hospital air?

A

Nosocomial Aspergillosis

Maintain spore-free environment – cleaning, physical barriers
Protect at-risk patients (HEPA filters)

17
Q

Treatment of Invasive Aspergillosis?

A

Voriconazole
Amphotericin B (Angioinvasive)
Echinocandins (caspofungin, anuidulafungin)

Surgery – resection of lesion
Stop immunosuppressive therapy, if possible
Prophylaxis (High risk pts. - hematological insufficiency)

18
Q

Mucormycosis (Mucor/Rhizopus) Risk Factors/Manifestations/Diagnosis/Managment

A

Risk Factors
Immunocompromised
Diabetes Mellitus
IVDU

Manifestations
ANGIOINVASIVE
Rhinocerebral, Pulmonary, GIT, Cutaneous

Diagnosis: Tissue biopsy- Non-septate hyphae

Management: Amphotericin B, Surgery

(Echinocandins and Azoles have NO activity)

19
Q

What are non-septate hyphae on tissue biopsy histology diagnostic of?

A

Mucormycosis (Mucor/Rhizopus)

20
Q

Cryptococcus Neoformans Risk Factors/Manifestations?

A

Yeast (encapsulated)

Risk Factors
Soil, avian faeces, rotting vegetation
Immunocompromised
* HIV
* Organ transplant
* Steroids
* Malignancy

Manifestations
Pulmonary
Skin
Bone
Cryptococcal Meningitis: Hematogenous spread from lungs=> Meningitis, confusion, coma, CN palsy

21
Q

Pathogenesis/Diagnosis/Therapy of Cryptococcal Meningitis

A

Pathogenesis
Hematogenous spread from lungs => Meningitis, confusion, coma, CN palsy

Diagnosis
Antigen Detection (CrAg) - serum, CSF

India Ink Stain – capsule

CSF
* Elevated opening pressure
* Elevated white cell count (lymphocytes)
* Microscopy and culture

Therapy for Cryptococcal Meningitis

Induction: ** Amphotericin B iv**, Flucytosine po (Minimum 2 weeks)

Consolidation: Fluconazole 400-800mg po (8 weeks)

Maintenance: Fluconazole 200-400mg po (Minimum 1 year)

Raised Intracranial Pressure: Lumbar taps, Ventriculo-peritoneal shunt

22
Q

Pneumocystis Jiroveci (aka Pneumocystis carinii) Risk Factors

A

Risk Factors
Disease only in immunocompromised
* HIV (CD4 count <200)
* Malignancy – especially ALL
* Transplant
* Immunosuppressive drugs
* Steroids

Predominantly pulmonary infection => Pneumocystis Pneumonia (PJP)

23
Q

Clinical Features/Diagnosis/Management of Pneumocystis Pneumonia (PJP)

A

Clinical Features
Fever
Dry cough
Progressive dyspnoea
Hypoxia
Respiratory failure

Respiratory examination may be normal

Diagnosis
CXR: Bilateral interstitial infiltrates

High resolution CT thorax: Ground-glass attenuation

BAL
* Grocott (silver) stain
* Direct fluorescent antibody staining
* PCR- NOT quantitative

Serum: BD-glucan
Elevated LDH

Managment
Cotrimoxazole – 3 weeks
Steroids – if pO2 < 7.3 mm Hg

Prophylaxis in at-risk groups
Segregation from other immunocompromised patient